<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7094090/results/search/test_trace/results.xml">
  <result pre="cell surface is of significant interest since it initiates the" exact="infection" post="process. Cryo-EM structure analysis has revealed that the binding"/>
  <result pre="disease and its epidemiology in an effort to uncover possible" exact="treatment" post="regimens, discover effective therapeutic agents, and develop vaccines. Figure"/>
  <result pre="large portion of these articles are about clinical manifestations and" exact="treatment" post="options, an increasing number of studies are focused on"/>
  <result pre="halt the progression of this epidemic disease and to prevent" exact="infection" post="and transmission in the future. Figure 4 Number of"/>
  <result pre="drug candidates such as remdesivir, baricitinib, and chloroquine for the" exact="treatment" post="of this disease. Table 1 Notable Journal Articles on"/>
  <result pre="Academy of Sciences, Wuhan, Chinab 12 Lancet Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory disease February 4, 2020 BenevolentAI,"/>
  <result pre="against influenza virus,20 has entered into a clinical trial for" exact="treatment" post="of SARS-CoV-2.21,22 The protease TMPRSS2 produced by the host"/>
  <result pre="Viral Infection Process target candidate full name role during viral" exact="infection" post="drug candidate 3CLpro coronavirus main protease 3CLpro a protease"/>
  <result pre="ACE2 is yet to be confirmed. ACE2 involvement with coronavirus" exact="infection" post="is of further interest since ACE2 is a potent"/>
  <result pre="PLpro lopinavir and ritonavir are approved drug combination for HIV" exact="infection" post="ritonavir19,37c 155213-67-5 darunavir33 206361-99-1 approved drug for HIV infection"/>
  <result pre="HIV infection ritonavir19,37c 155213-67-5 darunavir33 206361-99-1 approved drug for HIV" exact="infection" post="favipiravir (favilavir)29,36 259793-96-9 RdRp a purine nucleoside that acts"/>
  <result pre="block viral nucleotide synthesis to stop viral replication Ebola virus" exact="infection" post="ribavirin16,29−31a 36791-04-5 RSV infection, hepatitis C, some viral hemorrhagic"/>
  <result pre="elevate endosomal pH and interfere with ACE2 glycosylation malarial parasite" exact="infection" post="nitazoxanide29 55981-09-4 N/A a drug that may inhibit viral"/>
  <result pre="aforementioned potential drugs, together with patents disclosing small molecules for" exact="treatment" post="of SARS or MERS. The selection was based on"/>
  <result pre="Preparation of 3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid derivatives as cysLT2 receptor antagonists for" exact="treatment" post="of respiratory diseases Ono Pharmaceutical Co., Ltd., Japan WO2007120160"/>
  <result pre="between AT1 and AT2, which may be affected by coronavirus" exact="infection" post="and to alleviate viral-induced lung injury during the infection.24"/>
  <result pre="is limited clinical and basic research information at this time," exact="treatment" post="options for COVID-19 currently comprise investigational drugs and management"/>
  <result pre="biologics have the potential to broaden the spectrum of the" exact="treatment" post="options for coronavirus-induced diseases, leveraging prior knowledge and practices"/>
  <result pre="cytokines, interfering and other therapeutic RNAs, and vaccines for potential" exact="treatment" post="and/or prevention of SARS-related diseases from patents published from"/>
  <result pre="and methods of use thereof Humab, LLC 20080117 WO2008035894 viral" exact="infection" post="Preparation of antiviral antibody 3D8 fragments and their use"/>
  <result pre="Preparation of antiviral antibody 3D8 fragments and their use in" exact="treatment" post="of viral infection Sung Kyun Kwan University; Ajou University;"/>
  <result pre="antibody 3D8 fragments and their use in treatment of viral" exact="infection" post="Sung Kyun Kwan University; Ajou University; Invitroplant Co., Ltd."/>
  <result pre="20060519 WO2007044695 spike protein Neutralizing monoclonal anti-spike protein antibodies for" exact="diagnosis" post="and treatment of SARS-coronavirus-associated disease and screening of vaccine"/>
  <result pre="spike protein Neutralizing monoclonal anti-spike protein antibodies for diagnosis and" exact="treatment" post="of SARS-coronavirus-associated disease and screening of vaccine or anti-SARS"/>
  <result pre="protein antibodies for diagnosis and treatment of SARS-coronavirus-associated disease and" exact="screening" post="of vaccine or anti-SARS agent Dana-Farber Cancer Institute 20051007"/>
  <result pre="WO2006095180 S2 protein Human monoclonal antibodies against SARS-associated coronavirus and" exact="treatment" post="of patients with SARS Ultra Biotech Ltd.; University of"/>
  <result pre="antibody of SARS coronavirus N protein and its use in" exact="treatment" post="of SARS virus infections Chinese Academy of Sciences 20040715"/>
  <result pre="WO2005060520 spike protein Antibodies specific to SARS-CoV spike protein for" exact="diagnosis" post="and therapy of SARS and for screening of epitopic"/>
  <result pre="spike protein for diagnosis and therapy of SARS and for" exact="screening" post="of epitopic vaccines or anti-SARS therapeutics Dana-Farber Cancer Institute,"/>
  <result pre="for use in antigen detection, antibody production, and defense against" exact="infection" post="Genesis Biotech Inc. 20030908 US20050069869 spike protein SARS coronavirus"/>
  <result pre="interferon fusion proteins have been utilized as therapeutic agents for" exact="treatment" post="of viral infections for the past 20 years. A"/>
  <result pre="Patent application WO2005097165 claims a method for treating SARS viral" exact="infection" post="using IL-28A, IL-28B, and IL-29 cysteine variants conjugated to"/>
  <result pre="of an interferon fused with human serum albumin-binding peptide for" exact="treatment" post="of a wide range of diseases, including SARS. Specific"/>
  <result pre="authors demonstrated that SARSi-2, SARSi-3, SARSi-4, and SARSi-7-11 inhibited coronavirus" exact="infection" post="and replication in FRhk-4 cells. SARSi-4 was the most"/>
  <result pre="Raji B cells; and (4) elicit protection against a challenge" exact="infection" post="in an animal model. Patent application US20060002947 (Antigen Express,"/>
  <result pre="and SAB-301 were able to protect these mice from MERS-CoV" exact="infection" post="with a single prophylactic injection. Novavax announced on February"/>
  <result pre="announced on February 26, 202054 that it was beginning animal" exact="testing" post="on potential COVID-19 vaccine candidates due to their previous"/>
  <result pre="approach to prophylactic vaccines include the ability to mimic natural" exact="infection" post="to stimulate a more potent immune response as well"/>
  <result pre="well as biologics targeting complex molecular interactions involved in coronavirus" exact="infection" post="and replication. The drug-repurposing effort summarized in this report"/>
  <result pre="well as anti-inflammatory drugs. The potential impact of biologics for" exact="treatment" post="of coronavirus infections is promising and includes a wide"/>
  <result pre="for discovery and development of therapeutic agents and vaccines for" exact="treatment" post="of COVID-19 and coronavirus-related diseases. Because of limited space,"/>
  <result pre="current efforts involved in advancing more efficient and accurate COVID-19" exact="diagnosis" post="methods and products. Novel infectious diseases resulting from RNA"/>
  <result pre="repurposing has become one of the chosen solutions for immediate" exact="treatment" post="of SARS-CoV-2 infected individuals. Long-term drug development goals for"/>
  <result pre="industry include identification of inhibitors aimed at the replication or" exact="infection" post="processes associated with SARS-CoV-2 or other related coronaviruses, as"/>
  <result pre="et al. Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoV."/>
  <result pre="213–219. 10.1016/S0014-2999(00)00612-9.10980281 GuoD.Old weapon for new enemy: drug repurposing for" exact="treatment" post="of newly emerging viral diseases. Virol. Sin.2020, 10.1007/s12250-020-00204-7. [Epub"/>
  <result pre="10.1038/nature13027.24590073 RichardsonP.; GriffinI.; TuckerC.; SmithD.; OechsleO.; PhelanA.; StebbingJ.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory disease. Lancet2020, 395 (10223), e30–e31."/>
  <result pre="VogelL.; SubbaraoK.; MossB.Neutralizing antibody and protective immunity to SARS coronavirus" exact="infection" post="of mice induced by a soluble recombinant polypeptide containing"/>
 </snippets>
</snippetsTree>
